Jardine Matheson is making a powerful move by acquiring Australia’s I-MED for an impressive $2.4 billion enterprise value, dramatically boosting its healthcare portfolio. This bold step marks a strategic leap into the fast-growing world of medical diagnostics, positioning the company at the forefront of industry innovation
Italy’s Chiesi is gearing up to acquire US-listed KalVista Pharmaceuticals for an impressive $1.9 billion, signaling a bold leap to expand its rare disease and drug development portfolio, Reuters reports. This landmark deal highlights the growing surge of cross-border investments transforming the pharmaceutical landscape
Brazil’s healthcare industrial complex is locked in a fierce struggle against regulatory roadblocks, limited investment, and supply chain challenges-obstacles that are slowing its progress despite soaring demand, reports Valor International
The Japan Home Healthcare Market is poised for impressive expansion from 2025 to 2033, driven by a rapidly aging population and a booming demand for remote medical services, according to the latest market forecast report on vocal.media
Merck is scaling back its major operations in the UK, raising alarms about Britain’s capacity to retain its thriving life sciences sector amid rising costs and tangled regulations. Industry experts warn that this decision could put the future of the nation’s biotech industry at serious risk
Eli Lilly’s recent launch of its weight-loss drug in India is set to transform the competitive landscape of the burgeoning market. With obesity rates rising, rivals are now poised to accelerate their efforts to capture a share of this lucrative opportunity.
